Serina Therapeutics Business Summary

Serina Therapeutics, Inc. (SER) is a clinical-stage biotechnology company that operates primarily through a research and development business model focused on its proprietary polyoxazoline (POZ) platform. The company generates revenue through a combination of government grants, strategic collaborations, and potential future licensing fees for its drug delivery technology, which is designed to improve the safety and efficacy of small molecules, RNA therapeutics, and antibody-drug conjugates. Serina’s primary business segment is the development of its internal pipeline, led by SER-252 for advanced Parkinson’s disease—which received FDA IND clearance in January 2026—and SER-270 for Tardive dyskinesia. In the competitive landscape of advanced drug delivery and CNS-focused biopharma, Serina competes with firms such as Immunome, Hansa Biopharma, and Silo Pharma, positioning itself as a specialized alternative to traditional PEGylation technologies by offering a polymer platform with lower immunogenicity and higher drug-loading capacity. The company’s leadership is anchored by CEO Steven Ledger, who previously served as the firm’s CFO and brings over 35 years of experience in venture capital and operational roles at early-stage life science companies. The executive team includes Executive Chairman Simba Gill, Ph.D., a veteran biotech leader with a pedigree from Maxygen and Evelo Biosciences, and CFO Gregory Curhan. Serina was co-founded by J. Milton Harris, Ph.D., a pioneer in PEGylation technology, and Tacey Viegas, Ph.D., who serves as Chief Operating Officer. The technical leadership is further strengthened by Chief Scientific Officer Randall Moreadith, M.D., Ph.D., and Dr. Joshua Thomas, who was appointed VP and Head of Chemistry in late 2025. Notable institutional backing and board representation include Juvenescence, co-founded by director Gregory Bailey, alongside major shareholders such as Vanguard Group and Broadwood Capital.